These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20413122)

  • 1. Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic patients: A randomised trial.
    Solà R; Bruckert E; Valls RM; Narejos S; Luque X; Castro-Cabezas M; Doménech G; Torres F; Heras M; Farrés X; Vaquer JV; Martínez JM; Almaraz MC; Anguera A
    Atherosclerosis; 2010 Aug; 211(2):630-7. PubMed ID: 20413122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in LEP and NPY genes modify the response to soluble fibre Plantago ovata husk intake on cardiovascular risk biomarkers.
    Crescenti A; Solà R; Valls RM; Anguera A; Arola L
    Genes Nutr; 2013 Jan; 8(1):127-36. PubMed ID: 22669627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial.
    Salas-Salvadó J; Farrés X; Luque X; Narejos S; Borrell M; Basora J; Anguera A; Torres F; Bulló M; Balanza R;
    Br J Nutr; 2008 Jun; 99(6):1380-7. PubMed ID: 18031592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of soluble fiber (Plantago ovata husk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease.
    Solà R; Godàs G; Ribalta J; Vallvé JC; Girona J; Anguera A; Ostos M; Recalde D; Salazar J; Caslake M; Martín-Luján F; Salas-Salvadó J; Masana L
    Am J Clin Nutr; 2007 Apr; 85(4):1157-63. PubMed ID: 17413119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ispaghula husk in the treatment of hypercholesterolaemia: a double-blind controlled study.
    MacMahon M; Carless J
    J Cardiovasc Risk; 1998 Jun; 5(3):167-72. PubMed ID: 10201553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combining psyllium fiber with simvastatin in lowering cholesterol.
    Moreyra AE; Wilson AC; Koraym A
    Arch Intern Med; 2005 May; 165(10):1161-6. PubMed ID: 15911730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals.
    Giacco R; Clemente G; Luongo D; Lasorella G; Fiume I; Brouns F; Bornet F; Patti L; Cipriano P; Rivellese AA; Riccardi G
    Clin Nutr; 2004 Jun; 23(3):331-40. PubMed ID: 15158296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters.
    Fernandez-Martinez MN; Hernandez-Echevarria L; Sierra-Vega M; Diez-Liebana MJ; Calle-Pardo A; Carriedo-Ule D; Sahagún-Prieto AM; Anguera-Vila A; Garcia-Vieitez JJ
    BMC Complement Altern Med; 2014 Aug; 14():296. PubMed ID: 25112783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
    Insull W; Davidson MH; Kulkarni PM; Siddhanti S; Ciaccia AV; Keech CA
    Metabolism; 2005 Jul; 54(7):939-46. PubMed ID: 15988705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
    Jula A; Marniemi J; Huupponen R; Virtanen A; Rastas M; Rönnemaa T
    JAMA; 2002 Feb; 287(5):598-605. PubMed ID: 11829698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M; Volpe M; Massaad R; Davies MJ; Allen C
    Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a GFOD2 variant on responses in total and LDL cholesterol in Mexican subjects with hypercholesterolemia after soy protein and soluble fiber supplementation.
    Guevara-Cruz M; Lai CQ; Richardson K; Parnell LD; Lee YC; Tovar AR; Ordovás JM; Torres N
    Gene; 2013 Dec; 532(2):211-5. PubMed ID: 24064143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.